FLT3 Mutated AML: Are Triplets Better Than Doublets?
FLT3 tyrosine kinase inhibitor combination regimens may hold promise to not only improve outcomes for older individuals with FLT3-mutant but potentially for all patients , regardless of age or fitness.
Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients
Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.
Updates in the Treatment Landscape of AML
Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.
Marqibo for the Treatment of Older Patients With ALL
Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).